webinar register page

Webinar banner
Cholangiocarcinoma Case Notes: Exploring real-world use of PEMAZYRE®▼(pemigatinib) in the NHS
You are warmly invited to join Incyte’s upcoming virtual meeting in which a multidisciplinary UK panel will share personal insights into their use of the targeted therapy, PEMAZYRE®, in the treatment of patients with CCA.

UK Summary of Product Characteristics: PEMAZYRE® monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Drawing upon their extensive experience in the management of CCA, the panel will discuss important aspects of treatment, including molecular testing, clinical outcomes and how to manage toxicities and adverse events to help support patients on their treatment journey.

Your chair for this event will be Professor Jonathan Wadsley, Consultant Clinical Oncologist, Weston Park Hospital, Sheffield. He will be joined by Dr Roopinder Gillmore, Consultant Medical Oncologist at the Royal Free Hospital, London, and Megan Perry and Donna Hodge, both Clinical Nurse Specialists at Weston Park and the Royal Free, respectively.

Oct 12, 2022 05:00 PM in London

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: .